Primary Data on ATTR-Amyloidosis Prevalence Among Elderly Patients With Left Ventricular Hypertrophy in Russia
- PMID: 38742516
- DOI: 10.18087/cardio.2024.4.n2611
Primary Data on ATTR-Amyloidosis Prevalence Among Elderly Patients With Left Ventricular Hypertrophy in Russia
Abstract
Aim: To estimate the prevalence of amyloid cardiomyopathy (CM) caused by transthyretin amyloidosis (ATTR) and immunoglobulin light chain (AL) amyloidosis among patients aged >65 years with interventricular septal (IVS) hypertrophy of ≥14 mm.
Material and methods: From January through August 2023, 60 patients (mean age 7.2±7.3 years, 34 (56.67%) men) were enrolled. Patients meeting the inclusion criteria underwent an echocardiographic study with determining the myocardial longitudinal strain, myocardial scintigraphy with 99mTc-pyrfotech, myocardial single-photon emission computed tomography, measurement of N-terminal fragment of brain natriuretic peptide and troponin I, and the immunochemical study of serum and urine proteins with measurement of free light chains. In the presence of grades 2 and 3 radiopharmaceutical uptake according to scintigraphy, a molecular genetic study was performed for differential diagnosis of wild-type transthyretin amyloidosis (wtATTR) and hereditary/variant (hATTR) ATTR-CM.
Results: According to data of myocardial scintigraphy with 99mTc-pyrfotech, grade 3 uptake in the absence of monoclonal secretion was detected in 5 (8.3%) cases and grade 2 radiotracer uptake in the absence of monoclonal secretion was detected in 6 (10%) patients. Myeloma complicated by AL amyloidosis and primary AL amyloidosis were found in 5 (8.3%) patients.
Conclusion: Among patients aged ≥65 years with IVS hypertrophy ≥14 mm, amyloid CM was detected in 20% of cases (12 patients), including 5 cases (8.3%) of AL amyloidosis and 7 cases (11.7%) of ATTR amyloidosis.
Similar articles
-
Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis.Eur J Heart Fail. 2022 Sep;24(9):1677-1696. doi: 10.1002/ejhf.2589. Epub 2022 Aug 2. Eur J Heart Fail. 2022. PMID: 35730461
-
99m Technetium-pyrophosphate scintigraphy: a practical guide for early diagnosis of transthyretin amyloid cardiomyopathy.ESC Heart Fail. 2022 Feb;9(1):251-262. doi: 10.1002/ehf2.13693. Epub 2021 Nov 29. ESC Heart Fail. 2022. PMID: 34841715 Free PMC article. Review.
-
Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.Annu Rev Med. 2020 Jan 27;71:203-219. doi: 10.1146/annurev-med-052918-020140. Annu Rev Med. 2020. PMID: 31986086 Review.
-
Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.Eur Heart J. 2017 Oct 7;38(38):2879-2887. doi: 10.1093/eurheartj/ehx350. Eur Heart J. 2017. PMID: 29019612 Free PMC article.
-
Noninvasive risk stratification of patients with transthyretin amyloidosis.JACC Cardiovasc Imaging. 2014 May;7(5):502-10. doi: 10.1016/j.jcmg.2014.03.002. Epub 2014 Apr 9. JACC Cardiovasc Imaging. 2014. PMID: 24726252
MeSH terms
LinkOut - more resources
Medical
Research Materials
Miscellaneous